{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-003639","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.257522+00:00","generated_at":"2026-05-27T00:03:13.304617+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Roivant Q3 loss $208.9M; cash $5.2B; launches brepocitinib Ph2 in sarcoidosis","bullets":["Revenue $9.0M (-42% YoY); loss from continuing ops $208.9M vs. $5.1B income in prior year (Telavant gain).","Cash and marketable securities $5.2B at Dec 31; plus $75M VTAMA milestone and $113M from Immunovant private placement.","New brepocitinib Phase 2 in cutaneous sarcoidosis; topline data expected H2 2026.","Batoclimab pivotal trial results in MG and CIDP expected by March 31, 2025; IMVT-1402 pivotal trials initiated in GD and D2T RA.","LNP litigation vs. Moderna: summary judgment Q2/Q3 2025, jury trial Sept 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-003639","json":"https://secwatch.observer/filing/0001140361-25-003639.json","markdown":"https://secwatch.observer/filing/0001140361-25-003639.md","text":"https://secwatch.observer/filing/0001140361-25-003639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125003639/0001140361-25-003639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125003639/ef20043151_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:03:13.304617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}